Latest News-InnoCare Pharma Mediaroom_Page

InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

BEIJING, March 27, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the comp...

2022-03-28 10:48 2301

InnoCare Releases 2021 Annual Results and Business Highlights

BEIJING, March 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical ...

2022-03-23 08:08 3907

InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström's Macroglobulinemia in China

BEIJING, March 13, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical ...

2022-03-14 08:30 2400

InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China

BEIJING, March 1, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical c...

2022-03-02 10:37 2854

InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP

BEIJING, Feb. 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical c...

2022-02-22 17:09 2734

InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355

BEIJING, Jan. 18, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: ...

2022-01-18 14:51 2815

InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development

BEIJING, Jan. 7, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, ann...

2022-01-07 08:30 2790

Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH

BEIJING, Dec. 13, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, an...

2021-12-14 12:50 2464

InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List

BEIJING, Dec. 2, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech com...

2021-12-03 10:13 2780

InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA

BEIJING, Nov. 14, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech co...

2021-11-15 08:30 2766

InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development

BEIJING, Nov. 12, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, an...

2021-11-12 14:14 2285

InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH

BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, ann...

2021-11-09 13:06 2487

InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China

BEIJING, Oct. 19, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the Compa...

2021-10-19 12:56 2397

InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355

BEIJING, Sept. 17, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX:...

2021-09-17 20:00 5961

InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723

BEIJING, Aug. 30, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biopharmac...

2021-08-31 08:30 3147

InnoCare Releases 2021 Half Year Results and Business Highlights

BEIJING, Aug. 29, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical c...

2021-08-29 19:49 5297

InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332

BEIJING, Aug. 15, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company ...

2021-08-16 09:32 8427

InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP in China

BEIJING, Aug. 10, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical c...

2021-08-11 08:00 18087